May 8th 2024
Although several clinical trials have confirmed the safety and efficacy of rituximab in oncology and autoimmune disease, and even as off-label use in MS, real-world evidence is still necessary to help guide clinicians and managed care professionals in their treatment and coverage decision-making.
Cannabis Extract Treatment for MS Spasticity, Sativex, Opens in US for Phase 3 Trial
November 6th 2020A Phase 3 trial is in the works in the U.S. for Sativex (nabiximols), an oral spray that contains cannabis extracts, in treating spasticity — muscle stiffness or spasms — associated with multiple sclerosis (MS).
Read More
Prospective Study Identifies Factors Associated With Unemployment Among People With MS
October 25th 2020People with MS who are at risk for joblessness have poorer health-related habits and lower “locus of control” scores, according to findings by Kessler Foundation researcher Lauren Strober.
Read More
Similar Cancer Risk Between Patients With MS, General Population in the UK, Study Finds
October 23rd 2020Study found that while frequency of cancer among people with multiple sclerosis (MS) increased over time, the overall cancer risk is similar between patients with MS and the general population.
Read More
In Secondary-Progressive Multiple Sclerosis, Questions Abound, But So Do Breakthroughs
June 4th 2020Much remains unknown about how precisely multiple sclerosis occurs and advances in patients, but a growing body of research is helping scientists develop new ways to slow, and potentially stop, disease progression.
Read More